Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Section 32 Information
Geographic Data
Address: -
City: Silicon Valley,
State: CA
Zip: 94024
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$1B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,606,848Website Global Rank
6,485Website Monthly Traffic
Twitter Followers
Description
Section 32, the new venture fund launched by Bill Maris, was named in homage to Section 31, an intelligence agency from the Star Trek universe. Maris, the GV (Google Ventures) founder/former-CEO, has raised $150 million for the project that will focus on various investments. The fund will be run directly by Maris and primarily based out of San Diego.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2019 | Culture Biosciences | Venture Round | 0 |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 11/2021 | Mekonos | Series A | 0 |
| 3/2022 | Nucleai | Series B | 0 |
| 5/2021 | Phaidra | Seed Round | 0 |
| 11/2022 | MedCrypt | Series B | 0 |
| 7/2018 | Alector | Series E | 133M |
| 4/2018 | Vineti | Series B | 33.5M |
| 11/2021 | MedArrive | Series A | 0 |
| 11/2018 | Primer | Series B | 40M |
| 2/2021 | Miroculus | Series B | 45M |
| 8/2017 | Auris Health | Series D | 0 |
| 4/2022 | Parallel Finance | Venture Round | 0 |
| 5/2022 | Character Biosciences | Series A | 0 |
| 2/2019 | Teckro | Series C | 0 |
| 6/2021 | Primer | Series C | 0 |
| 5/2020 | Phaidra | Seed Round | 1.5M |
| 12/2021 | Dialpad | Series F | 0 |
| 3/2022 | SandboxAQ | Series D | - |
| 3/2021 | Meatable | Series A | 47M |
| 7/2022 | Phaidra | Series A | 0 |
| 12/2021 | ONI | Series B | 75M |
| 7/2017 | Embark | Seed Round | 5.5M |
| 10/2018 | Nusano | Series A | - |
| 7/2020 | Sema4 | Series C | 121M |
| 2/2022 | Syllable | Series C | 0 |
| 1/2023 | Forward Networks | Series D | 0 |
| 4/2023 | Function Oncology | Series A | 28M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 9/2021 | Cohere | Series A | 40M |
| 7/2018 | Metromile | Series E | 90M |
| 10/2017 | Lime | Series B | 50M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 7/2018 | Cue | Series B | 0 |
| 10/2020 | Vineti | Series C | 33M |
| 4/2021 | C2i Genomics | Series B | 0 |
| 2/2020 | Vineti | Series C | 35M |
| 7/2022 | BigHat Biosciences | Series B | 0 |
| 3/2022 | Satellite Bio | Series A | 0 |
| 1/2021 | EQRx | Series B | 500M |
| 6/2021 | Syllable | Series B | 28M |
| 8/2019 | Sema4 | Series B | 120M |
| 1/2022 | Metaphysic | Venture Round | 7.5M |
| 6/2021 | ImmuneID | Series A | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 7/2019 | Cradle Genomics | Series A | 0 |
| 6/2023 | AltPep | Series B | 0 |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 10/2021 | Gretel | Series B | 0 |
| 6/2021 | Faro | Series A | 15M |
| 12/2019 | XOKind | Seed Round | 3.3M |
| 8/2017 | Teckro | Series B | 10M |
| 5/2022 | Legacy | Series B | 25M |
| 8/2020 | Freenome | Series C | 270M |
| 12/2019 | XOKind | Pre Seed Round | 3.6M |
| 2/2023 | Faro | Series A | 20M |
| 5/2017 | Kobalt | Series D | 75M |
| 10/2017 | Kobalt | Series D | 14M |
| 7/2020 | Evidation Health | Series D | 45M |
| 10/2022 | Nested Therapeutics | Series A | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 10/2021 | ScienceIO | Seed Round | 0 |
| 7/2018 | Octave Bioscience | Series A | 14M |
| 12/2021 | Nodexus | Series A | 30M |
| 2/2018 | Celularity | Series A | 250M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 10/2017 | Dave | Series A | 13.3M |
| 6/2022 | Manifold Bio | Series A | 0 |
| 1/2019 | Ciitizen | Series A | 17M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 1/2020 | EQRx | Series A | 200M |
| 10/2021 | Culture Biosciences | Series B | 0 |
| 9/2018 | Fulcrum Therapeutics | Series B | 80M |
| 7/2017 | BloomAPI | Seed Round | 2.4M |
| 10/2022 | Neocis | Series D | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 10/2020 | Neocis | Series D | 72M |
| 4/2021 | Current Health | Series B | 43M |
| 10/2020 | Dialpad | Series E | 100M |
| 5/2019 | Thrive Earlier Detection | Series A | 110M |
| 7/2019 | Freenome | Series B | 160M |
| 2/2022 | Cohere | Series B | 0 |
| 12/2021 | Verge Genomics | Series B | 98M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 3/2020 | Culture Biosciences | Series A | 0 |
| 5/2019 | MedCrypt | Series A | 6.3M |
| 8/2017 | Freenome | Series A | 7M |
| 11/2020 | WithMe Health | Series B | 25M |
| 11/2019 | Legacy | Seed Round | 3.5M |
| 6/2019 | Legacy | Pre Seed Round | 1.5M |
| 9/2021 | TrialSpark | Series C | 156M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 12/2021 | Exai Bio | Series A | 67.5M |
| 12/2017 | Relay Therapeutics | Series B | 63M |
| 4/2019 | Embark | Series A | 12M |
| 8/2017 | Coinbase | Series D | 108.1M |
| 12/2020 | Octave Bioscience | Series B | 32M |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 8/2022 | Spectral | Venture Round | 0 |
| 8/2022 | Inworld AI | Series A | 0 |
| 6/2023 | Delve Bio | Series A | 0 |
| 10/2021 | Wise Systems | Series C | 0 |
| 9/2017 | Dialpad | Series C | 17M |
| 7/2018 | Dialpad | Series D | 50M |
| 10/2022 | Stairwell | Series B | 0 |
| 2/2023 | Faro Health | Series A | 0 |
| 7/2022 | Swadesh | Pre Seed Round | 2.3M |
| 4/2023 | Function Oncology | Series A | 0 |
| 2/2023 | Faro Health | Series A | 0 |
| 1/2023 | Forward Networks | Series D | 0 |
| 11/2022 | MedCrypt | Series B | 0 |
| 10/2022 | Neocis | Series D | 0 |
| 10/2022 | Stairwell | Series B | 0 |
| 10/2022 | Nested Therapeutics | Series A | 0 |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 8/2022 | Spectral | Venture Round | 0 |
| 8/2022 | Inworld AI | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
